Teva Pharmaceutical Industries' (TEVA) unit Teva Pharmaceuticals said Wednesday that the US Food and Drug Administration has approved Ajovy for the preventive treatment of episodic migraine in children and adolescents aged 6-17 years who weigh 45 kilograms or more.
Preventive treatment may help decrease the frequency of migraine attacks, the company said, adding Ajovy is given once a month and available for in-office or at home use.
Teva shares were rising 1.1% in recent trading.
Price: 15.89, Change: +0.17, Percent Change: +1.11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.